Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML

Jorge Cortes • 7 Dec 2025
ASH 2025
Chronic Myeloid Leukemia Leukemia Asciminib
ASC4FIRST

Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses patient-reported outcomes from the ASC4FIRST study (NCT04971226) of asciminib versus investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia (CML). Dr Cortes reports significant improvements in quality of life for patients receiving asciminib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jorge Cortes

Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML 2:09
Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML
Jorge Cortes • 4 Sep 2025
Aiming to further improve the outcomes of patients with CML 1:39
Aiming to further improve the outcomes of patients with CML
Jorge Cortes • 4 Sep 2025
Efficacy and safety of olutasidenib monotherapy in relapsed/refractory AML 1:49
Efficacy and safety of olutasidenib monotherapy in relapsed/refractory AML
Jorge Cortes • 4 Sep 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101 1:45
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals